Randomized double-blind placebo-controlled prospective, parallel, single centre clinical trial of bacterial vaccine (BACTEK) sublingual (oral mucosa) in patients with repeat bronchospasm for the immunomodulatory eficacy evaluation, security and clinical impact

Trial Profile

Randomized double-blind placebo-controlled prospective, parallel, single centre clinical trial of bacterial vaccine (BACTEK) sublingual (oral mucosa) in patients with repeat bronchospasm for the immunomodulatory eficacy evaluation, security and clinical impact

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs MV 130 (Primary)
  • Indications Bronchospasm
  • Focus Registrational; Therapeutic Use
  • Acronyms MV130
  • Sponsors Inmunotek
  • Most Recent Events

    • 22 Dec 2015 Planned End Date changed from 1 Nov 2016 to 1 May 2016, according to ClinicalTrials.gov record.
    • 22 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 May 2016, according to ClinicalTrials.gov record.
    • 22 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top